Lilly to appeal FDA's approvable letter for Arxxant

Share this article:
Eli Lilly says it will appeal the FDA's decision to issue an "approvable letter" that requests an additional efficacy study for Arxxant, its new drug for moderate to severe nonproliferative diabetic retinopathy. Its appeal will be based on unmet medical need for the drug, demonstrated efficacy and Arxxant's "robust safety profile."
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...